182 related articles for article (PubMed ID: 15993080)
1. 8-Azapurines as new inhibitors of cyclin-dependent kinases.
Havlicek L; Fuksova K; Krystof V; Orsag M; Vojtesek B; Strnad M
Bioorg Med Chem; 2005 Sep; 13(18):5399-407. PubMed ID: 15993080
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
3. Biaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part I.
Trova MP; Barnes KD; Barford C; Benanti T; Bielaska M; Burry L; Lehman JM; Murphy C; O'Grady H; Peace D; Salamone S; Smith J; Snider P; Toporowski J; Tregay S; Wilson A; Wyle M; Zheng X; Friedrich TD
Bioorg Med Chem Lett; 2009 Dec; 19(23):6608-12. PubMed ID: 19846305
[TBL] [Abstract][Full Text] [Related]
4. The design and synthesis of purine inhibitors of CDK2. III.
Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
[TBL] [Abstract][Full Text] [Related]
5. A novel series of highly potent 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitors.
Gucký T; Jorda R; Zatloukal M; Bazgier V; Berka K; Řezníčková E; Béres T; Strnad M; Kryštof V
J Med Chem; 2013 Aug; 56(15):6234-47. PubMed ID: 23829517
[TBL] [Abstract][Full Text] [Related]
6. Heterobiaryl purine derivatives as potent antiproliferative agents: inhibitors of cyclin dependent kinases. Part II.
Trova MP; Barnes KD; Alicea L; Benanti T; Bielaska M; Bilotta J; Bliss B; Duong TN; Haydar S; Herr RJ; Hui Y; Johnson M; Lehman JM; Peace D; Rainka M; Snider P; Salamone S; Tregay S; Zheng X; Friedrich TD
Bioorg Med Chem Lett; 2009 Dec; 19(23):6613-7. PubMed ID: 19854650
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
[TBL] [Abstract][Full Text] [Related]
9. 2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors.
Moravec J; Krystof V; Hanus J; Havlícek L; Moravcová D; Fuksová K; Kuzma M; Lenobel R; Otyepka M; Strnad M
Bioorg Med Chem Lett; 2003 Sep; 13(18):2993-6. PubMed ID: 12941319
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activities of C-2, N-9 substituted 6-benzylaminopurine derivatives as cyclin-dependent kinase inhibitor.
Oh CH; Lee SC; Lee KS; Woo ER; Hong CY; Yang BS; Baek DJ; Cho JH
Arch Pharm (Weinheim); 1999 Jun; 332(6):187-90. PubMed ID: 10399486
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor.
Krystof V; McNae IW; Walkinshaw MD; Fischer PM; Müller P; Vojtesek B; Orság M; Havlícek L; Strnad M
Cell Mol Life Sci; 2005 Aug; 62(15):1763-71. PubMed ID: 16003486
[TBL] [Abstract][Full Text] [Related]
12. The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
Ferguson M; Luciani MG; Finlan L; Rankin EM; Ibbotson S; Fersht A; Hupp TR
Cell Cycle; 2004 Jan; 3(1):80-9. PubMed ID: 14657672
[TBL] [Abstract][Full Text] [Related]
13. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity.
Hamed OA; Abou-Elmagd El-Sayed N; Mahmoud WR; F Elmasry G
Bioorg Chem; 2024 Jun; 147():107413. PubMed ID: 38696844
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and in vitro evaluation of novel 2,6,9-trisubstituted purines acting as cyclin-dependent kinase inhibitors.
Legraverend M; Ludwig O; Bisagni E; Leclerc S; Meijer L; Giocanti N; Sadri R; Favaudon V
Bioorg Med Chem; 1999 Jul; 7(7):1281-93. PubMed ID: 10465404
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
[TBL] [Abstract][Full Text] [Related]
17. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells.
David-Pfeuty T
Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500
[TBL] [Abstract][Full Text] [Related]
18. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells.
Akiyama T; Yoshida T; Tsujita T; Shimizu M; Mizukami T; Okabe M; Akinaga S
Cancer Res; 1997 Apr; 57(8):1495-501. PubMed ID: 9108451
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of guanidino analogues of roscovitine.
Dolečková I; Cesnek M; Dračinský M; Brynda J; Voller J; Janeba Z; Kryštof V
Eur J Med Chem; 2013 Apr; 62():443-52. PubMed ID: 23399722
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells.
Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM
Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]